Europe will lose out to countries like the U.S. and Japan on new medical research, trials and treatments unless draft rules reforming the European pharmaceutical landscape change, the CEO of Danish drugmaker Novo Nordisk warned on Thursday.
https://www.pharmalive.com/wp-content/uploads/2023/03/ReutersNovoNordisk3-3-2023.jpg7201080Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-03-02 18:00:572023-03-03 11:57:23Europe will lose out on medical innovation if draft EU reforms pass – Novo Nordisk CEO